Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)

Kalff, A; Khong, T; Ramachandran, M; Walker, P; Schwarer, A; Roberts, AW; Campbell, P; Filshie, R; Norton, S; Reynolds, J; Young, M; Pierceall, W; Thakurta, A; Guo, M; Oppermann, U; Wang, M; Ren, Y; Kennedy, N; Parekh, S; Spencer, A

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)

journal contribution

posted on 2024-06-13, 15:00 authored by A Kalff, T Khong, M Ramachandran, P Walker, A Schwarer, AW Roberts, P Campbell, R Filshie, S Norton, J Reynolds, M Young, W Pierceall, A Thakurta, M Guo, U Oppermann, M Wang, Y Ren, N Kennedy, S Parekh, A Spencer

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)

History

Related Materials

1.
DOI - Is version of https://doi.org/10.1080/10428194.2021.1948030

Location

Abingdon, Eng.

Language

eng

Author URL

https://www.ncbi.nlm.nih.gov/pubmed/34263697

Publication classification

C1 Refereed article in a scholarly journal

Journal

Leukemia and Lymphoma

Volume

62

Pagination

2981-2991

ISSN

1042-8194

eISSN

1029-2403

Issue

12

Publisher

Taylor & Francis

Usage metrics

Keywords

cereblon pathway lenalidomide maintenance mass cytometry Myeloma 3201 Cardiovascular medicine and haematology 3204 Immunology

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)

History

Related Materials

Location

Language

Author URL

Publication classification

Journal

Volume

Pagination

ISSN

eISSN

Issue

Publisher

Usage metrics

Categories

Keywords

Licence

Exports